Access cutting-edge chronic graft versus host disease treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access chronic graft versus host disease specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related chronic graft versus host disease treatment provided free
This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease. Chronic graft versus host disease remains a major complication of stem cell transplantation and can involve multiple organ systems. Belumosudil is a ROCK2 selective inhibitor that works to reduce the immune system response causing the chronic graft versus host disease. Giving belumosudil may better treat patients with chronic graft versus host disease and prevent the n
Sponsor: Fred Hutchinson Cancer Center
Check if you qualify for this chronic graft versus host disease clinical trial in New York, NY
If you're searching for chronic graft versus host disease treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chronic graft versus host disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.